Dietary Protein and Amino Acid Supplementation in Inflammatory Bowel Disease Course: What Impact on the Colonic Mucosa?
Inflammatory bowel diseases (IBD), after disease onset, typically progress in two cyclically repeated phases, namely inflammatory flare and remission, with possible nutritional status impairment. Some evidence, either from epidemiological, clinical, and experimental studies indicate that the quantity and the quality of dietary protein consumption and amino acid supplementation may differently influence the IBD course according to the disease phases. For instance, although the dietary protein needs for mucosal healing after an inflammatory episode remain undetermined, there is evidence that amino acids derived from dietary proteins display beneficial effects on this process, serving as building blocks for macromolecule synthesis in the wounded mucosal area, energy substrates, and/or precursors of bioactive metabolites. However, an excessive amount of dietary proteins may result in an increased intestinal production of potentially deleterious bacterial metabolites. This could possibly affect epithelial repair as several of these bacterial metabolites are known to inhibit colonic epithelial cell respiration, cell proliferation, and/or to affect barrier function. In this review, we present the available evidence about the impact of the amount of dietary proteins and supplementary amino acids on IBD onset and progression, with a focus on the effects reported in the colon.
UMR 914 INRA/AgroParisTech/Université Paris Saclay, Nutrition Physiology and Ingestive Behavior, 16 rue Claude Bernard, F-75005 Paris, France. sandra.vidal@agroparistech.fr.
Sandra
S
Vidal-Lletjós
UMR 914 INRA/AgroParisTech/Université Paris Saclay, Nutrition Physiology and Ingestive Behavior, 16 rue Claude Bernard, F-75005 Paris, France. martin.beaumont@agroparistech.fr.
Martin
M
Beaumont
UMR 914 INRA/AgroParisTech/Université Paris Saclay, Nutrition Physiology and Ingestive Behavior, 16 rue Claude Bernard, F-75005 Paris, France. daniel.tome@agroparistech.fr.
Daniel
D
Tomé
UMR 914 INRA/AgroParisTech/Université Paris Saclay, Nutrition Physiology and Ingestive Behavior, 16 rue Claude Bernard, F-75005 Paris, France. robert.benamouzig@aphp.fr.|Department of Gastroenterology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, F-93000 Bobigny, France. robert.benamouzig@aphp.fr.
Robert
R
Benamouzig
UMR 914 INRA/AgroParisTech/Université Paris Saclay, Nutrition Physiology and Ingestive Behavior, 16 rue Claude Bernard, F-75005 Paris, France. francois.blachier@agroparistech.fr.
François
F
Blachier
UMR 914 INRA/AgroParisTech/Université Paris Saclay, Nutrition Physiology and Ingestive Behavior, 16 rue Claude Bernard, F-75005 Paris, France. annaig.lan@agroparistech.fr.
Annaïg
A
Lan
D000596:Amino Acids / Q000008:administration & dosage*; D000818:Animals; D003106:Colon / Q000378:metabolism / Q000382:microbiology; D004044:Dietary Proteins / Q000008:administration & dosage*; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004847:Epithelial Cells / Q000378:metabolism; D000069196:Gastrointestinal Microbiome; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000378:metabolism* / Q000382:microbiology / Q000503:physiopathology; D007413:Intestinal Mucosa / Q000378:metabolism* / Q000382:microbiology; D014945:Wound Healing
D000596:Amino Acids; D004044:Dietary Proteins
amino acid supplementation; dietary proteins; inflammatory bowel disease